EPA-DHA Composition with 2:1 Ratio for Long-Term Liver Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for liver diseases, such as fatty liver disease, are limited and ineffective, particularly in terms of patient compliance and dosage requirements, especially for long-term treatment options.
Innovation Solution
A composition comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of at least 2:1, formulated as a pharmaceutically acceptable medicament, preferably in an oil-in-water emulsion, with specific ratios and additives for effective treatment and prevention of liver diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If long-term treatment is provided to ensure therapeutic efficacy, then treatment effectiveness is improved, but patient compliance deteriorates
Solution Approach 1:
The patent applies preliminary action by administering the EPA/DHA composition within a short time window (e.g., first 4 weeks) after diagnosis, before the disease progresses to more severe stages. This early intervention achieves long-lasting therapeutic effects (lasting months to years) without requiring prolonged treatment, thereby improving patient compliance while maintaining therapeutic efficacy.
2Ease of manufacture
If commercially available emulsion is used, then treatment is accessible, but dosage requirements become unusable
Solution Approach 1:
The patent changes the critical parameter of EPA/DHA ratio from the conventional 1:1 ratio to a minimum 2:1 ratio, with preferred ratios of 4.5:1 to 6:1. This parameter change enables achieving therapeutic effects at significantly lower dosages (e.g., 1-100 mg/kg body weight per day), making the treatment accessible and practical for patients while maintaining efficacy.
3Ease of operation
If oral supplementation is used, then patient compliance is improved, but treatment effectiveness deteriorates
Solution Approach 1:
The patent uses an oil-in-water emulsion formulation as an intermediary that combines the advantages of both oral administration (ease of use, patient compliance) and parenteral administration (rapid onset, reliable effectiveness). The emulsion form allows for convenient oral or intravenous administration while ensuring adequate bioavailability and therapeutic response, resolving the contradiction between compliance and effectiveness.
Data Source
AI summary
The present invention relates to the treatment of liver diseases. In particular, it relates to a composition for use in treating and/or preventing a liver disease in a subject, wherein said composition comprises eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the ratio of EPA to DHA is at least 2:1.